News Category: General

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO –(BUSINESS WIRE)–Sep. 1, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi’s 17 th Annual BioPharma Conference Fireside Chat: Thursday, September 8, 2022 at 1:00 p.m.

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

SAN DIEGO –(BUSINESS WIRE)–Aug. 4, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID ® (pimavanserin)